Radiation for Stage 4 Breast Cancer: 155 Real Stories

Metastatic breast cancer to the mandible with later lung and liver spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER/PR negative, HER2 weak-to-moderate.

Metastatic Site: mandible/bone, lungs, liver

She died 6 months after diagnosis of mandibular metastasis from breast cancer, after further spread to the lungs and liver.

PubMed CentralRead more →

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Stage IV Breast Cancer: Queen's Patient Story

Patient Info: Queen, Female, Under 40 | Stage IV

As of June 2025, Queen was living with Stage IV/metastatic breast cancer after multiple surgeries, setbacks, spread, and another tumor, while focusing on faith, self-advocacy, and living each day fully.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Recurrent breast cancer with pleural disease: capecitabine stopped after cardiac complications

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: pleura

As of May 2025, she was living with recurrent breast cancer involving the pleura after stopping capecitabine because of major cardiac complications; cardiac symptoms were medically managed with stable NYHA class II dyspnea at 3-month follow-up.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Breast cancer first discovered after it had already spread to the spinal cord

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Estrogen receptor-positive; progesterone receptor-negative; HER2 score 0

Metastatic Site: intramedullary spinal cord (D11-D12); bilateral…

Her paraplegia did not improve after spinal radiation, and she died from disease progression 3 months after the breast-cancer diagnosis.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Brain and Leptomeningeal Metastases Responding to Intrathecal Treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain, leptomeninges

More than 5 years after her September 2019 diagnosis, neurological symptoms had resolved, cerebrospinal fluid remained negative for tumor cells, and maintenance treatment was continuing in February 2025.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

Metastatic Breast Cancer Returning About 20 Years After Initial Treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones

About 20 years after her original breast-cancer treatment and sustained remission, bone biopsy confirmed metastatic recurrence; she became too unwell for planned cancer therapy and chose supportive care.

PubMed CentralRead more →

Stage 4 hormone receptor-positive breast cancer: remission with PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HR-positive breast cancer with HER2-low/negative recurrence, and pathogenic BRCA2 R2318* mutation.

Metastatic Site: pleura

As of January 2025, she had maintained complete response for 36 months after sequential FEC/docetaxel and olaparib for hormone receptor-positive, HER2-negative/HER2-low metastatic breast cancer with BRCA2 R2318* mutation.

PubMed CentralRead more →

Breast Cancer Recurring Years Later With Leptomeningeal Spread and a Brief Response to Trastuzumab Deruxtecan

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-low

Metastatic Site: peritoneum, retroperitoneum, bones, leptomeninges

Died on May 10, 2024, about 18 years after her April 2006 breast-cancer diagnosis and about 6 years after metastatic recurrence.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed CentralRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Paclitaxel-Related Macular Edema During Treatment for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, HER2-negative

Cancer treatment continued with eribulin after paclitaxel was stopped because of vision toxicity in early 2021.

PubMed CentralRead more →

Stage IV luminal B HER2-negative breast cancer with liver-limited metastasis resected after systemic therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Luminal B; HER2-negative

Metastatic Site: liver

After liver segmentectomy for breast-cancer liver metastasis, follow-up imaging showed no remaining liver nodes, and she remained fit, well, disease-free, and on maintenance letrozole plus goserelin.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Stage IV Breast Cancer: Nina's Survivor Story

Patient Info: Nina, Female, Under 40 | Stage IV

Metastatic Site: Spine

As of November 2024, Nina had Stage IV metastatic breast cancer with prior spine metastasis, remained on indefinite infusions and medications, and had current scans showing no evidence of disease.

The Patient StoryRead more →